Julie Lin, MD, MPH, FASN

Principal of QHIA Consulting

Dr. Lin is currently Senior Vice President, Clinical Development and Clinical Pharmacology at Travere Therapeutics. She received her undergraduate degree in Biology from Harvard College (Cambridge, MA), her MD from Columbia College of Physicians and Surgeons (New York, NY), and her MPH degree from Harvard School of Public Health. After completing an Internal Medicine residency and Nephrology fellowship at the Presbyterian Hospital, Columbia University, she joined the faculty of Brigham and Women’s Hospital (BWH) and Harvard Medical School where she held multiple leadership positions including Associate Program Director of the joint Brigham/Massachusetts General Hospital Nephrology Fellowship, Chair of the Renal Division’s T32 grant committee at BWH, and founder and director of the Outpatient Kidney Biopsy program. As a NIH funded physician-scientist, her research focused on biomarker and lifestyle predictors of progressive chronic kidney disease (CKD), impact of CKD on cognitive functioning, living kidney donors and glomerular diseases.

Dr. Lin made a transition to industry in 2012 and has held positions of increasing responsibility in clinical development at Genzyme, Dimension Therapeutics (acquired by Ultragenyx in 2017), Sanofi, and Travere Therapeutics. Her extensive work in early clinical development programs has provided insights into career topics for research scientists (PhD), regulatory leads and program managers (PharmD, Masters, PhD), as well as physicians (MD, MBBS).

Dr. Lin on LinkedIn

Dr. Lin on Google Scholar